Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis—EARLY TAVR Trial

November 26, 2024

Source: New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2405880

Keywords:

Author(s): Philippe Généreux, Allan Schwartz, J. Bradley Oldemeyer, Philippe Pibarot, David J. Cohen, Philipp Blanke, Brian R. Lindman, Vasilis Babaliaros, William F. Fearon, David V. Daniels, Adnan K. Chhatriwalla, Clifford Kavinsky, Hemal Gada, Pinak Shah, Molly Szerlip, Thom Dahle, Kashish Goel, William O’Neill, Tej Sheth, Charles J. Davidson, Raj R. Makkar, Heather Prince, Yanglu Zhao, Rebecca T. Hahn, Jonathon Leipsic, Björn Redfors, Stuart J. Pocock, Michael Mack, Martin B. Leon

The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes. Superiority testing was conducted in the intention-to-treat population. A total of 901 patients underwent randomization—455 patients were assigned to the TAVR group, and 446 patients were assigned to the clinical surveillance group. The mean age of the patients was 75.8 years, the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 1.8 percent, and 83.6 percent of patients were classified as low surgical risk. A primary end point event occurred in 122 patients (26.8 percent) in the TAVR group and 202 patients (45.3 percent) in the clinical surveillance group (hazard ratio, 0.50; 95 percent confidence interval, 0.40 to 0.63; P